We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible Staphylococcus aureus. Apramycin demonstrated an MIC50/MIC90 of 8/16 μg/mL. No strains had an MIC above the epidemiological cutoff value of 32 μg/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted.
Keywords: Activity spectrum; Aminoglycoside; Antibiotic; Apramycin; Gentamicin; Natural product; Repurposing; Staphylococcus aureus; Synergy.
Copyright © 2018 Elsevier Inc. All rights reserved.